07 July 2014 : Original article
Early Conversion from Twice-Daily Tacrolimus to Once-Daily Extended Formulation in Renal Transplant Patients Before Hospital Discharge
Martin JannotABDFG, Ingrid MassonE, Eric AlamartineE, Christophe MariatACDEFDOI: 10.12659/AOT.890262
Ann Transplant 2014; 19:320-324
Abstract
BACKGROUND: Although the once-daily formulation of tacrolimus (ADVAGRAF™) is approved in renal transplantation to be used immediately after surgery, conventional twice-daily formulation offers better flexibility to adjust the dosage of tacrolimus during the initial period of transplantation.
MATERIAL AND METHODS: We retrospectively report here our initial experience with a strategy of an early conversion from PROGRAF™ to ADVAGRAF™ before hospital discharge.
RESULTS: Forty-eight de novo renal transplant recipients were started on PROGRAF™ and then switched to ADVAGRAF™ after a median time of 11 days and 4.5 days, respectively, before discharge. In terms of tacrolimus exposure, great inter-individual heterogeneity was noted, with 56% of patients experiencing a clinically significant modification in post-switch tacrolimus blood trough levels. Modification in post-switch drug exposure was poorly predicted by change in tacrolimus daily dosage. Six-month post-transplant outcome was similar in patients converted to ADVAGRAF™ to that of patients who had remained on PROGRAF™ during the same period of time. Our data suggest that an early conversion from PROGRAF™ to ADVAGRAF™ during the hospital stay may be safely undertaken, provided tacrolimus exposure is tightly monitored in patients.
CONCLUSIONS: This strategy might represent an alternative to the immediate post-transplant introduction of ADVAGRAF™ and needs to be clinically validated in large-scale controlled trials.
Keywords: Drug Monitoring, immunosuppresive agent, Kidney Transplantation, Tacrolimus
In Press
Original article
Outcomes of Combined Liver-Kidney Transplantation in Polycystic Liver and Kidney DiseaseAnn Transplant In Press; DOI: 10.12659/AOT.947639
Most Viewed Current Articles
03 Jan 2023 : Original article 6,893
Impact of Autologous Stem Cell Transplantation on Primary Central Nervous System Lymphoma in First-Line and...DOI :10.12659/AOT.938467
Ann Transplant 2023; 28:e938467
15 Aug 2023 : Review article 6,848
Free-Circulating Nucleic Acids as Biomarkers in Patients After Solid Organ TransplantationDOI :10.12659/AOT.939750
Ann Transplant 2023; 28:e939750
16 May 2023 : Original article 6,597
Breaking Antimicrobial Resistance: High-Dose Amoxicillin with Clavulanic Acid for Urinary Tract Infections ...DOI :10.12659/AOT.939258
Ann Transplant 2023; 28:e939258
28 May 2024 : Original article 5,949
Effect of Dexmedetomidine Combined with Remifentanil on Emergence Agitation During Awakening from Sevoflura...DOI :10.12659/AOT.943281
Ann Transplant 2024; 29:e943281